Uyarıcı Maddeler ve Kullanım Bozuklukları
Özet
Amfetaminler, metamfetamin ve kokain gibi uyarıcı maddelerin tarihçesi, epidemiyolojisi, nörofarmakolojisi, klinik etkileri ve tedavi yöntemleri incelenmektedir. Geleneksel bitkilerden izole edilen ve zamanla sentetik olarak geliştirilen bu maddeler, başlangıçta tıbbi amaçlarla kullanılmış olsa da kötüye kullanım potansiyelleri nedeniyle yasal düzenlemelere tabi tutulmuştur. Dünya genelinde esrardan sonra en yaygın yasa dışı uyuşturucu sınıfını oluşturan uyarıcılar, merkezi ve periferik sinir sistemindeki dopamin, norepinefrin ve serotonin monoaminerjik yolları üzerinden etki ederek öfori, uyanıklık artışı ve hiperaktiviteye yol açar. Kronik kullanımları; paranoya ve halüsinasyon gibi psikotik semptomların yanı sıra inme, enfarktüs ve böbrek yetmezliği gibi ciddi tıbbi durumlara zemin hazırlar. Bilişsel Davranışçı Terapi (BDT) ve acil durum yönetimi gibi psikososyal yaklaşımlar bağımlılık tedavisinin temelini oluştururken, akut intoksikasyon durumlarında benzodiazepinler ilk seçenek olarak tercih edilmektedir. Halihazırda FDA tarafından onaylanmış spesifik bir ilaç bulunmamakla birlikte, naltrekson, bupropion ve disülfiram gibi ajanların kullanımına yönelik klinik araştırmalar ve agonist ikame tedavileri umut vadetmektedir.
The history, epidemiology, neuropharmacology, clinical effects, and treatment methods of stimulant substances such as amphetamines, methamphetamine, and cocaine are examined. These substances, which were isolated from traditional plants and synthetically developed over time, were initially used for medical purposes but were subjected to legal regulations due to their high abuse potential. Formulating the second most common class of illicit drugs worldwide after cannabis, stimulants act through monoaminergic pathways of dopamine, norepinephrine, and serotonin in the central and peripheral nervous systems, leading to euphoria, increased alertness, and hyperactivity. Their chronic use paves the way for severe medical conditions including stroke, myocardial infarction, and kidney failure, alongside psychotic symptoms such as paranoia and hallucinations. Psychosocial approaches like Cognitive Behavioral Therapy (CBT) and contingency management form the cornerstone of addiction treatment, whereas benzodiazepines are preferred as the first-line option in acute intoxication cases. Although there is currently no specific medication approved by the FDA, clinical research regarding the use of agents such as naltrexone, bupropion, and disulfiram, as well as agonist replacement therapies, shows promise.
Referanslar
Hunt D, Kuck S, Truitt L. Methamphetamine Use: Lessons Learned. Cambridge, MA: Abt Associates Inc.; 2006. (Contract No. 209730)
Rasmussen N. Making the first anti-depressant: amphetamine in American medicine, 1929-1950. Journal of the History of Medicine and Allied Sciences. 2006;61(3):288-323. doi.org/10.1093/jhmas/jrj039
Goode E. Drugs in American society. 6th ed. New York: McGraw-Hill; 2005.
Vearrier D, Greenberg MI, Miller SN, et al. Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Disease-a-Month. 2012;58:38-89. doi:10.1016/j.disamonth.2011.09.004
Maxwell JC, Brecht M-L. Methamphetamine: here we go again? Addictive Behaviors. 2011;36(12): 1168–1173. doi.org/10.1016/j.addbeh.2011.07.017
Siefried KJ, Acheson LS, Lintzeris N, et al. Pharmacological treatment of methamphetamine/amphetamine dependence: A Systematic Review. CNS Drugs. 2020; 34:337–365. doi.org/10.1007/s40263-020-00711-x
Substance Abuse and Mental Health Services Administration 2020. Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. (23/01/2022 tarihinde https://www.samhsa.gov/data/ adresinden indirilmiştir.)
Avrupa Uyuşturucu ve Uyuşturucu Bağımlılığını İzleme Merkezi 2021. Avrupa Uyuşturucu Raporu 2021: Eğilimler ve Gelişmeler. (24/01/2022 tarihinde doi:10.2810/384120 adresinden ulaşılmıştır.)
United Nations Office on Drugs and Crime 2021. World Drug Report 2021. (25/01/2022 tarihinde www.unodc.org/unodc/en/data-and-analysis/wdr2021.html adresinden ulaşılmıştır.)
Substance Abuse and Mental Health Service Administration 2018-2019. National survey of drug use and health. (01/02/2021 tarihinde www.samhsa.gov adresinden ulaşılmıştır.)
Docherty JR, Alsufyani HA. Pharmacology of Drugs Used as Stimulants. The Journal of Clinical Pharmacology. 2021;61(2):53–69. doi: 10.1002/jcph.1918
Fleckenstein AE, Volz TJ, Riddle EL, et al. New Insights into the Mechanism of Action of Amphetamines. The Annual Review of Pharmacology and Toxicology. 2007;47:681-698. doi.org/10.1146/annurev.pharmtox.47.120505.105140.
Howell LL, Kimmel HL. Monoamine transporters and psychostimulant addiction. Biochemical Pharmacology. 2008;75(1):196-217. doi.org/10.1016/j.bcp.2007.08.003
Sulzer D, Sonders MS, Poulsen NW, et al. Mechanisms of neurotransmitter release by amphetamines: a review. Progress in Neurobiology. 2005;75(6):406-433. doi:10.1016/j.pneurobio.2005.04.003
Katzung BG. Basic and Clinical Pharmacology. 8th ed. New York: Lange Medical/McGraw-Hill; 2001.
Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009;104(7):1085–1099.
Ciccarone D. Stimulant Abuse: Pharmacology, Cocaine, Methamphetamine, Treatment, Attempts at Pharmacotherapy. Primary Care: Clinics in Office Practice. 2011;38(1):41–58. doi: 10.1016/j.pop.2010.11.004
European Monitoring Centre for Drugs and Drug Addiction 2014. Exploring methamphetamine trends in Europe. (13/03/2018 tarihinde http://www.emcdda.europa.eu/system/ files/publications/787/TDAU14001ENN_460800.pdf adresinden ulaşılmıştır.)
Faraone SV. The Pharmacology of Amphetamine and Methylphenidate: Relevance to the Neurobiology of Attention-Deficit/Hyperactivity Disorder and Other Psychiatric Comorbidities. Neuroscience & Biobehavioral Reviews. 2018;87:255–270. doi:10.1016/j.neubiorev.2018.02.001
Evren C, Bozkurt M. Metamfetamin Güncellemesi: Son Zamanlarda Karşılaştığımız Eski Bir Problem. Dusunen Adam The Journal of Psychiatry and Neurological Sciences. 2018; 31: 1-10 doi:10.5350/DAJPN20183101001.
Kudlacek O, Hofmaier T, Luf Aet al. Cocaine adulteration. Journal of Chemical Neuroanatomy. 2017;1(83-84):75–81. doi:10.1016/j.jchemneu.2017.06.001
Frances RJ, Miller SI, Mack AH. Clinical Textbook of Addictive Disorders. Third ed. New York: The Guilford Press; 2005.
Barnett G, Hawks R, Resnick R J. Cocaine pharmacokinetics in humans. Journal of Ethnopharmacology. 1981;3(2-3):353-366. doi:10.1016/0378-8741(81)90063-5.
Jenkins AJ, Keenan RM, Henningfield JE. Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration. Journal of Analytical Toxicology. 2002;26(7):382-392.
Brandt L, Chao T, Comer SD, et al. Pharmacotherapeutic strategies for treating cocaine use disorder—what do we have to offer? Addiction. 2021;116(4): 694–710. doi: 10.1111/add.15242
Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochemical Pharmacology .2008;75(1): 218-265.
Williams MJ, Adinoff B. The role of acetylcholine in cocaine addiction. Neuropsychopharmacology. 2008;33(8): 1779-1797.
Al Suwaidi J, Ali WM, Aleryani SL. Cardiovascular complications of Khat. Clinica Chimica Acta. 2013; 419: 11-14. doi:10.1016/j.cca.2013.01.007.
Iversen L, White M, Treble R. Designer psychostimulants: Pharmacology and differences. Neuropharmacology. 2014;87:59-65. doi:10.1016/j.neuropharm.2014.01.015
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Current HIV/AIDS Reports. 2005;2(4):194–199.
Gossop M, Griffiths P, Powis B, et al. Cocaine: patterns of use, route of administration, and severity of dependence. The British Journal of Psychiatry. 1994;164(5):660–664.
Romanelli F, Smith KM. Clinical effects and management of methamphetamine abuse. Pharmacotherapy. 2006; 26(8): 1148-1156. doi:10.1592/phco.26.8.1148.
Bonate PL, Swann A, Silverman PB. Context-dependent cross-sensitization between cocaine and amphetamine. Life Sciences. 1997; 60(1): PL1-7. doi:10.1016/S0024-3205(96)00591-7.
Mahoney JJ, Kalechstein AD, , De La Garza R, et al. Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants. The American Journal On Addiction. 2008; 17(2): 83-98. doi:10.1080/10550490701861201.
Coffey SF, Dansky BS, Carrigan MH, et al. Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. Drug and Alcohol Dependence. 2000; 59(3): 277-286. doi.org/10.1016/S0376-8716(99)00126-X.
Kılıç FS. Bağımlılık ve Uyarıcı Maddeler. Osmangazi Journal of Medicine. 2016; 38 (Special Issue 1): 55-60. DOI: http://dx.doi.org/10.20515/otd.50661.
Angrist B, Engel J, Oreland L, et al. Clinical effects of central nervous system stimulants: a selective update. New York: Raven Press; 1987.
Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, et al. Methamphetamine Treatment Project. Risk factors for suicide attempts in methamphetamine-dependent patients. American journal on addictions. 2008;17(1):24-27.
Akindipe T, Wilson D, Stein DJ. Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. Metabolic Brain Disease. 2014;29:351–357.
Gouzoulis-Mayfrank E, Härtel-Petri R, Hamdorf W,et al. Methamphetamine-relateddisorders. Deutsches Ärzteblatt international. 2017;114:455-641.
Richards JR, Albertson TE, Derlet RW, et al. Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review. Drug and Alcohol Dependence. 2015;150:1-13.
Paulus MP, Stewart JL. Methamphetamine Use Disorder: The Next Addiction Crisis. JAMA Psychiatry. 2020;77(9):959–966. doi: 10.1001/jamapsychiatry.2020.0246
Phillips KA, Epstein DH, Preston KL. Psychostimulant addiction treatment. Neuropharmacology. 2014; 87: 150–160. doi:10.1016/j.neuropharm.2014.04.002
Ronsley C, Nolan S, Knight R, et al. Treatment of stimulant use disorder: A systematic review of reviews. PLoS ONE. 2020; 15(6): e0234809. doi:10.1371/journal.pone.0234809
De Crescenzo F, Ciabattini M, D’Alò GL, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis. PLoS medicine. 2018;15(12):e1002715.
Newton TF, Kalechstein AD, Duran S, et al. Methamphetamine abstinence syndrome: preliminary findings. American Journal on Addictions. 2004;13(3):248-255.
Zorick T, Nestor L, Miotto K, et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction. 2010; 105(10):1809-1818.
Indave BI, Minozzi S, Pani PP, et al. Antipsychotic medications for cocaine dependence. Cochrane Database of Systematic Reviews. 2016; 3(3):CD006306.doi:10.1002/14651858.CD006306.pub3.
Pani PP, Trogu E, Vacca R, et al. Disulfiram for the treatment of cocaine dependence. Cochrane Database of SystematicReviews. 2010;(1):Cd007024
Johnson BA, Ait-Daoud N, Wang XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry.2013;70(12):1338–1346.
Elkashef A, Holmes TH, Bloch DA,et al. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction. 2005; 100(1):91-101.
Brensilver M, Heinzerling KG, Shoptaw S. Pharmacotherapy of amphetamine-type stimulant dependence: An update. Drug and Alcohol Dependence. 2013;32(5):449–460. doi:10.1111/dar.12048
Xiaoshan T, Junjie Y, Wenqing W, et al. Immunotherapy for treating methamphetamine, heroin and cocaine use disorders. Drug Discovery Today. 2020;25(3):610-619.
Chan B, Kondo K, Freeman M, et al. Pharmacotherapy for cocaine use disorder—a systematic review and meta-analysis. Journal of general internal medicine. 2019; 34(12): 2858-2873. doi:10.1007/s11606-019-05074-8
Courtney KE, Ray LA. Methamphetamine: An Update on Epidemiology, Pharmacology, Clinical Phenomenology, and Treatment Literature. Drug and Alcohol Dependence. 2014;1:11–21. doi:10.1016/j.drugalcdep.2014.08.003
